Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT03392415
Active, not recruiting Not applicable

The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion

NCT03392415 · tracked via the Priya Life Science Denmark tracker
Sponsor
Leif Thuesen
Phase
Not applicable
Started
2018-06-01
Last updated
2026-08-06

Condition(s) studied

Chronic Total Occlusion of Coronary ArteryHeart FailureAngina Pectoris

Investigational drug(s) / intervention(s)

CTO PCI

CTO PCI: attempted percutaneous coronary intervention of the chronic total coronary occlusion

Study summary

Randomized registry for the study of CTO PCI as adjunction to optimal medical therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * ≥1 CTO lesion amenable to PCI. * Stable and stabilized coronary artery disease * Symptoms (angina pectoris or shortness of breath) and/or signs of reversible perfusion defect by SPECT, PET or MR and/or angiographic/echocardiographic indication of reversible ischemia. * CTO lesion in a major coronary vessel supplying a significant myocardial territory (vessel diameter usually ≥3mm). Exclusion Criteria: * Expected survival \<1 year. * Renal failure on dialysis. * Stable non-CTO lesions treated within one month. * Declined informed consent. * Regarding CMR: allergy to contrast medium, severe obesity, claustrophobia and certain metallic implants

Primary outcome measure(s)

  • All-cause mortality — a minimal follow-up of 6 months
    All-cause mortality after inclusion of 2000 patients
  • Quality of life assessment — 6 months.
    Quality of life assessment by 12-Item Short Form Survey Instrument (SF-12v2)

Trial sites (1)

FacilityCityRegionStatus
Aalborg University Hospital Aalborg Denmark

More Leif Thuesen trials in Denmark

The Nordic Baltic Chronic Total Occlusion (CTO) Arrhythmia Study Active, not recruiting

Other trials for the same condition

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin Recruiting
Heart Rehabilitation for All Active, not recruiting
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes Recruiting
Danish Pragmatic Randomized Trial to Evaluate the Effect of HeartLogic-Guided Management on Heart Failure Outcomes Recruiting
Personalized Evaluation of Susptected Myocardial Ischemia Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03392415 on ClinicalTrials.gov ↗ ← All trials in Denmark